A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors (NCT06244485)

🧪 Interventions in This Study

• Valemetostat tosylate (DRUG)
• T-DXd (DRUG)
• Dato-DXd (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (35 Sites)

Showing the first 25 of 35 sites.

• City of Hope At Orange County Lennar Foundation Cancer Center — Irvine, California
• Sharp Memorial Hospital — San Diego, California
• Brcr Medical Center, Inc Dba Boca Raton Clinical Research — Plantation, Florida
• University of Hawaii At Manoa — Honolulu, Hawaii
• University of Chicago Medical Center — Chicago, Illinois
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Memorial Sloan-Kettering Cancer Center (Mskcc) - New York — New York, New York
• Clinical Research Alliance — Westbury, New York
• Unc Hospitals — Chapel Hill, North Carolina
• The Cleveland Clinic Foundation — Cleveland, Ohio
• Providence Portland Medical Center — Portland, Oregon
• Mary Crowley Cancer Research Centers — Dallas, Texas
• Ut Southwestern Medical Center — Dallas, Texas
• University of Texas M. D. Anderson Cancer Center — Houston, Texas
• Next Virginia — Fairfax, Virginia
• Fred Hutchinson Cancer Center — Seattle, Washington
• Medical College of Wisconsin — Milwaukee, Wisconsin
• Peking University Third Hospital — Beijing,
• Sun Yat-Sen University, Cancer Center — Guangzhou,
• SunYat-Sen University Cancer Center — Guangzhou,
• Harbin Medical Univeristy Cancer Hospital — Heilongjiang,
• Hunan Cancer Hospital — Hunan,
• Jilin Cancer Hospital — Jilin City,
• Jinana Center Hosptial — Shandong,
• IRCCS Istituto Scientifico Romagnolo Per — Cesena,

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.